Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study

The aim of this study was to test whether a low dose of interferon-α-2b (IFN-α2b) enhances the clinical outcome of docetaxel (DXT) in patients with castration-resistant prostate cancer (CRPC). A prospective controlled trial of 40 CRPC patients receiving 5 mg of prednisone twice daily was conducted,...

Full description

Saved in:
Bibliographic Details
Main Authors: LI, YUN-FEI, WANG, QIN-ZHANG, ZHANG, TAO-TAO, LI, LEI, WANG, JIANG-PING, DING, GUO-FU, HE, DA-LIN
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2014
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3861530/
https://ncbi.nlm.nih.gov/pubmed/24348833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2013.1653
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items